AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 2499185 — intervention group
Group type: EXPERIMENTAL
Intervention: Mannitol solution (296 mOsm/kg)
Number of subjects: 10
Study 2499185 — intervention group
Group type: EXPERIMENTAL
Intervention: Mannitol solution (449 mOsm/kg)
Number of subjects: 10
Study 2499185 — intervention group
Group type: EXPERIMENTAL
Intervention: Mannitol solution (704 mOsm/kg)
Number of subjects: 10
Study 2499185 — intervention group
Group type: EXPERIMENTAL
Intervention: Mannitol solution (1481 mOsm/kg)
Number of subjects: 10
Study 2499185 — intervention group
Group type: EXPERIMENTAL
Intervention: Orange juice (585 mOsm/kg)
Number of subjects: 10
Study 31418621 — intervention group
Group type: COMPARATOR
Intervention: Topical cantharidin (control group A)
Number of subjects: 40
Study 31418621 — intervention group
Group type: EXPERIMENTAL
Intervention: Intralesional tuberculin PPD (group B)
Number of subjects: 40
Study 30707135 — intervention group
Group type: EXPERIMENTAL
Intervention: Breakfast consumption (BC)
Number of subjects: 16
Study 30707135 — intervention group
Group type: COMPARATOR
Intervention: Breakfast omission (BO)
Number of subjects: 16
Study 28976919 — intervention group
Group type: EXPERIMENTAL
Intervention: Wearable camera methodology (Kids’Cam Tonga)
Number of subjects: 72
Study 28976919 — intervention group
Group type: EXPERIMENTAL
Intervention: Improvements to housing stock
Number of subjects: 72
Study 26501503 — intervention group
Group type: EXPERIMENTAL
Intervention: Detailed procedural instructions with principles studied before training
Number of subjects: 24
Study 26501503 — intervention group
Group type: EXPERIMENTAL
Intervention: General procedural instructions
Number of subjects: 24
Study 26501503 — intervention group
Group type: EXPERIMENTAL
Intervention: Detailed procedural instructions
Number of subjects: 24
Study 24242024 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified busulfan-fludarabine (mBuF) regimen
Number of subjects: 105
Study 24242024 — intervention group
Group type: COMPARATOR
Intervention: Modified busulfan-cyclophosphamide (mBuCy) regimen
Number of subjects: 105
Study 21164305 — intervention group
Group type: EXPERIMENTAL
Intervention: Operative group (n = 45)
Number of subjects: 73
Study 21164305 — intervention group
Group type: COMPARATOR
Intervention: Nonoperative group (n = 28)
Number of subjects: 73
Study 19915681 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin and etoposide (PE) regimen
Number of subjects: 10262
Study 19915681 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin-based regimens
Number of subjects: 10262
Study 19915681 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic cranial irradiation
Number of subjects: 10262
Study 19915681 — intervention group
Group type: EXPERIMENTAL
Intervention: Good performance status (PS)
Number of subjects: 10262
Study 19915681 — intervention group
Group type: COMPARATOR
Intervention: Cyclophosphamide, doxorubicin, and vincristine-based regimens
Number of subjects: 10262
Study 16409331 — intervention group
Group type: EXPERIMENTAL
Intervention: NiTi-TEE
Number of subjects: 50
Study 16409331 — intervention group
Group type: COMPARATOR
Intervention: K3
Number of subjects: 50
Study 15064661 — intervention group
Group type: EXPERIMENTAL
Intervention: NormLoudn
Number of subjects: 21
Study 15064661 — intervention group
Group type: COMPARATOR
Intervention: LessLoudn
Number of subjects: 21
Study 15064661 — intervention group
Group type: COMPARATOR
Intervention: Speech recognition scores for NormLoudn
Number of subjects: 21
Study 15064661 — intervention group
Group type: COMPARATOR
Intervention: Speech recognition scores for LessLoudn
Number of subjects: 21
Study 11171788 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol
Number of subjects: 121
Study 11171788 — intervention group
Group type: COMPARATOR
Intervention: Captopril
Number of subjects: 121
Study 9230237 — intervention group
Group type: EXPERIMENTAL
Intervention: Nedocromil sodium
Number of subjects: 31
Study 8480272 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 gram of prophylactic imipenem administered intravenously every eight hours for two weeks
Number of subjects: 74
Study 8480272 — intervention group
Group type: COMPARATOR
Intervention: No antibiotic treatment
Number of subjects: 74
Study 2887081 — intervention group
Group type: EXPERIMENTAL
Intervention: Primidone (62.5 mg X 1 up to 250 mg X 3 daily)
Number of subjects: 13
Study 2887081 — intervention group
Group type: COMPARATOR
Intervention: Propranolol (20 mg X 3 daily)
Number of subjects: 13
Study 2887081 — intervention group
Group type: EXPERIMENTAL
Intervention: Primidone
Number of subjects: 13
Study 2887081 — intervention group
Group type: COMPARATOR
Intervention: Placebo and Propranolol
Number of subjects: 13
Study 30378129 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided injection
Number of subjects: 47
Study 30378129 — intervention group
Group type: COMPARATOR
Intervention: Blind injection
Number of subjects: 47
Study 27974307 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified hospital menu with higher energy options
Number of subjects: 122
Study 27974307 — intervention group
Group type: COMPARATOR
Intervention: Standard menu
Number of subjects: 122
Study 27974307 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 122
Study 26130302 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% whey protein-enriched water (178 kJ)
Number of subjects: 60
Study 26130302 — intervention group
Group type: EXPERIMENTAL
Intervention: 4% whey protein-enriched water (348 kJ)
Number of subjects: 60
Study 26130302 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% sucrose-enriched water (157 kJ)
Number of subjects: 60
Study 26130302 — intervention group
Group type: EXPERIMENTAL
Intervention: 4% sucrose-enriched water (314 kJ)
Number of subjects: 60
Study 26130302 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% sucrose-enriched water (785 kJ)
Number of subjects: 60
Study 26130302 — intervention group
Group type: COMPARATOR
Intervention: Sweetened water control
Number of subjects: 60
Study 23804631 — intervention group
Group type: EXPERIMENTAL
Intervention: Asunaprevir 200 mg twice daily + PEG-IFN + ribavirin
Number of subjects: 47
Study 23804631 — intervention group
Group type: EXPERIMENTAL
Intervention: Asunaprevir 600 mg twice daily + PEG-IFN + ribavirin
Number of subjects: 47
Study 23804631 — intervention group
Group type: EXPERIMENTAL
Intervention: Asunaprevir 600 mg once daily + PEG-IFN + ribavirin
Number of subjects: 47
Study 23804631 — intervention group
Group type: COMPARATOR
Intervention: Placebo + PEG-IFN + ribavirin
Number of subjects: 47
Study 21668321 — intervention group
Group type: EXPERIMENTAL
Intervention: Breathing retraining (12 individual sessions)
Number of subjects: 40
Study 18769963 — intervention group
Group type: EXPERIMENTAL
Intervention: Alendronate (10 mg/day for 3 years)
Number of subjects: 17
Study 18769963 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study 16790627 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (1 microg/kg initial dose followed by continuous infusion of 0.5 microg.kg(‐1).h(‐1))
Number of subjects: 60
Study 16790627 — intervention group
Group type: COMPARATOR
Intervention: Propofol (3 mg/kg initial dose followed by continuous infusion of 100 microg.kg(‐1).min(‐1))
Number of subjects: 60
Study 12923821 — intervention group
Group type: EXPERIMENTAL
Intervention: DA agonist (lisuride=LIS)
Number of subjects: 36
Study 12923821 — intervention group
Group type: EXPERIMENTAL
Intervention: DA antagonist (fluphenazine=FLU)
Number of subjects: 36
Study 12923821 — intervention group
Group type: COMPARATOR
Intervention: High basal cortisol levels
Number of subjects: 36
Study 12923821 — intervention group
Group type: COMPARATOR
Intervention: Low basal cortisol levels
Number of subjects: 36
Study 12696319 — intervention group
Group type: EXPERIMENTAL
Intervention: Trapezoidal classroom shape
Number of subjects: 0
Study 12696319 — intervention group
Group type: COMPARATOR
Intervention: Traditional rectangular classroom shape
Number of subjects: 0
Study 9287629 — intervention group
Group type: EXPERIMENTAL
Intervention: Teaching hardiness
Number of subjects: 0
Study 8463932 — intervention group
Group type: EXPERIMENTAL
Intervention: Stress Management Training (SMT)
Number of subjects: 19
Study 8463932 — intervention group
Group type: COMPARATOR
Intervention: Standard outpatient treatment (Control)
Number of subjects: 19
Study 3517475 — intervention group
Group type: EXPERIMENTAL
Intervention: BAY m 1099 (25, 50, 100, 200 mg)
Number of subjects: 42
Study 3517475 — intervention group
Group type: EXPERIMENTAL
Intervention: BAY o 1248 (10, 20, 40 mg)
Number of subjects: 42
Study 3517475 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study 29194765 — intervention group
Group type: EXPERIMENTAL
Intervention: Toceranib (TOC) 2.75 mg/kg EOD
Number of subjects: 88
Study 29194765 — intervention group
Group type: COMPARATOR
Intervention: Vinblastine (VBL) 2.5 mg/m2 weekly × 4 then EOW
Number of subjects: 88
Study 27559981 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser acupuncture
Number of subjects: 66
Study 27559981 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 66
Study 24836151 — intervention group
Group type: EXPERIMENTAL
Intervention: Antisocial in-group member
Number of subjects: 0
Study 24836151 — intervention group
Group type: EXPERIMENTAL
Intervention: Prosocial out-group member
Number of subjects: 0
Study 24836151 — intervention group
Group type: COMPARATOR
Intervention: Control agents (moral information removed)
Number of subjects: 0
Study 22569079 — intervention group
Group type: EXPERIMENTAL
Intervention: Water immersion insertion and CO2 insufflation (water/CO2)
Number of subjects: 404
Study 22569079 — intervention group
Group type: COMPARATOR
Intervention: Water insertion and air insufflation (water/air)
Number of subjects: 404
Study 22569079 — intervention group
Group type: COMPARATOR
Intervention: CO2 insufflation during both insertion and withdrawal (CO2/CO2)
Number of subjects: 404
Study 22569079 — intervention group
Group type: COMPARATOR
Intervention: Air insufflation during both insertion and withdrawal (air/air)
Number of subjects: 404
Study 20393740 — intervention group
Group type: EXPERIMENTAL
Intervention: Alternation flicker technology
Number of subjects: 68
Study 20393740 — intervention group
Group type: COMPARATOR
Intervention: Digital photography inspection
Number of subjects: 68
Study 19146152 — intervention group
Group type: EXPERIMENTAL
Intervention: Tuigua manipulation combined with quadriceps exercise
Number of subjects: 48
Study 19146152 — intervention group
Group type: COMPARATOR
Intervention: Manipulation for osteoarthritis in Tuina Xue (Control)
Number of subjects: 48
Study 15824212 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin (80 mg/d)
Number of subjects: 20
Study 15824212 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 12625145 — intervention group
Group type: EXPERIMENTAL
Intervention: Simultaneous dosing (artesunate 200 mg/d plus mefloquine 250 mg/d from day 1 to day 3)
Number of subjects: 104
Study 12625145 — intervention group
Group type: COMPARATOR
Intervention: Sequential dosing (artesunate 200 mg/d for 3 days plus mefloquine 250 mg on day 2 and 500 mg on day 3)
Number of subjects: 104
Study 12412178 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine mouthwash (MO; 14 patients)
Number of subjects: 26
Study 12412178 — intervention group
Group type: COMPARATOR
Intervention: Magic mouthwash (MG; 12 patients)
Number of subjects: 26
Study 9589525 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal cord injury (SCI)
Number of subjects: 453
Study 9589525 — intervention group
Group type: EXPERIMENTAL
Intervention: Traumatic brain injury (TBI)
Number of subjects: 453
Study 9589525 — intervention group
Group type: COMPARATOR
Intervention: General population (controls)
Number of subjects: 453
Study 8029260 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose human leukocyte alpha-interferon (IFN-alpha) treatment
Number of subjects: 15
Study 8029260 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 2929931 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical application of 2% lignocaine
Number of subjects: 0
Study 31155869 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxibustion therapy
Number of subjects: 60
Study 31155869 — intervention group
Group type: COMPARATOR
Intervention: Manual acupuncture
Number of subjects: 60
Study 31155869 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (Moxibustion and Acupuncture)
Number of subjects: 60
Study 28333939 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine 20 mg slow-release three times daily
Number of subjects: 109
Study 28333939 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 109
Study 28333939 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 109
Study 25813692 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI
Number of subjects: 438
Study 25813692 — intervention group
Group type: COMPARATOR
Intervention: non-MRI
Number of subjects: 438
Study 25813692 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI (cT1 subgroup)
Number of subjects: 438
Study 25813692 — intervention group
Group type: COMPARATOR
Intervention: non-MRI (cT1 subgroup)
Number of subjects: 438
Study 23459753 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 × 20 g whey protein every 3 h (INT)
Number of subjects: 24
Study 23459753 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 × 10 g whey protein every 1.5 h (PULSE)
Number of subjects: 24
Study 23459753 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 × 40 g whey protein every 6 h (BOLUS)
Number of subjects: 24
Study 20809354 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone administered cognitive behavioral therapy
Number of subjects: 127
Study 20809354 — intervention group
Group type: COMPARATOR
Intervention: Telephone administered supportive emotion‐focused therapy
Number of subjects: 127
Study 19356666 — intervention group
Group type: EXPERIMENTAL
Intervention: Photodynamic therapy using 'Photogem'
Number of subjects: 72
Study 19356666 — intervention group
Group type: EXPERIMENTAL
Intervention: Photosens
Number of subjects: 72
Study 19356666 — intervention group
Group type: COMPARATOR
Intervention: Surgical treatment
Number of subjects: 72
Study 17123204 — intervention group
Group type: EXPERIMENTAL
Intervention: MIME robotic device (bilateral, unilateral, and combined bilateral and unilateral training)
Number of subjects: 0
Study 17123204 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy
Number of subjects: 0
Study 17123204 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined unilateral and bilateral robotic training
Number of subjects: 0
Study 17123204 — intervention group
Group type: EXPERIMENTAL
Intervention: Robot-assisted treatment (all types)
Number of subjects: 0
Study 12827582 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfentanil 10 micro g/kg
Number of subjects: 80
Study 12827582 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil 1 micro g/kg
Number of subjects: 80
Study 12827582 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil 2 micro g/kg
Number of subjects: 80
Study 12827582 — intervention group
Group type: COMPARATOR
Intervention: Saline (placebo)
Number of subjects: 80
Study 10747343 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol (25 mg twice daily for 5 months)
Number of subjects: 406
Study 10747343 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 406
Study 9373227 — intervention group
Group type: EXPERIMENTAL
Intervention: Early enteral feeding by nasojejunal tube
Number of subjects: 29
Study 9373227 — intervention group
Group type: COMPARATOR
Intervention: Parenteral nutrition by central venous catheter
Number of subjects: 29
Study 1539787 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral airways
Number of subjects: 36
Study 1539787 — intervention group
Group type: COMPARATOR
Intervention: Nasopharyngeal airways
Number of subjects: 36
Study 29461674 — intervention group
Group type: COMPARATOR
Intervention: Balanced salt solution (BSS)
Number of subjects: 69
Study 29461674 — intervention group
Group type: COMPARATOR
Intervention: Air-tamponade
Number of subjects: 69
Study 30634209 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole CDBBES recipe (containing leeches and equivalent insects)
Number of subjects: 76
Study 30634209 — intervention group
Group type: EXPERIMENTAL
Intervention: CDBBES recipe (removing leech and gradfly)
Number of subjects: 76
Study 30634209 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 76
Study 24667813 — intervention group
Group type: EXPERIMENTAL
Intervention: VACS Index
Number of subjects: 324
Study 24667813 — intervention group
Group type: EXPERIMENTAL
Intervention: Restricted Index
Number of subjects: 324
Study 21971750 — intervention group
Group type: EXPERIMENTAL
Intervention: BTX‐A (Xeomin) injected into the deep and superficial finger (100 units) and wrist flexors (50 units)
Number of subjects: 18
Study 21971750 — intervention group
Group type: COMPARATOR
Intervention: No injection (Control group)
Number of subjects: 18
Study 21971750 — intervention group
Group type: EXPERIMENTAL
Intervention: BTX‐A (Xeomin)
Number of subjects: 18
Study 19940853 — intervention group
Group type: EXPERIMENTAL
Intervention: CPAP therapy
Number of subjects: 40
Study 19940853 — intervention group
Group type: COMPARATOR
Intervention: Antidepressant medication
Number of subjects: 40
Study 18474534 — intervention group
Group type: EXPERIMENTAL
Intervention: Early Gp IIb-IIIa inhibitors
Number of subjects: 1662
Study 18474534 — intervention group
Group type: EXPERIMENTAL
Intervention: Early abciximab
Number of subjects: 1662
Study 15983677 — intervention group
Group type: EXPERIMENTAL
Intervention: Streptokinase (SK) 1.5 million units
Number of subjects: 50
Study 15983677 — intervention group
Group type: EXPERIMENTAL
Intervention: Streptokinase (SK) 2.5 million units
Number of subjects: 50
Study 11794455 — intervention group
Group type: EXPERIMENTAL
Intervention: 100% oxygen at 10 L/min through a facemask
Number of subjects: 100
Study 11794455 — intervention group
Group type: COMPARATOR
Intervention: Air
Number of subjects: 100
Study 10524419 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperfractionation
Number of subjects: 30
Study 10524419 — intervention group
Group type: COMPARATOR
Intervention: Conventional fractionation
Number of subjects: 30
Study 7739097 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane anesthesia (end‐tidal concentration 4.5%)
Number of subjects: 106
Study 7739097 — intervention group
Group type: COMPARATOR
Intervention: Halothane anesthesia (end‐tidal concentration 1.6%)
Number of subjects: 106
Study 1791060 — intervention group
Group type: EXPERIMENTAL
Intervention: Dextroamphetamine (5 and 10 mg orally, 1 hr prior to test)
Number of subjects: 3
Study 1791060 — intervention group
Group type: EXPERIMENTAL
Intervention: Yogic meditation
Number of subjects: 3
Study 1791060 — intervention group
Group type: COMPARATOR
Intervention: Placebo (lactose capsule)
Number of subjects: 3
Study 6808820 — intervention group
Group type: EXPERIMENTAL
Intervention: Encainide
Number of subjects: 8
Study 6808820 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 30919735 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrical stimulation with the Veinplicity® device followed by a tourniquet (intervention group 2)
Number of subjects: 141
Study 30919735 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrical stimulation without a tourniquet (intervention group 1)
Number of subjects: 141
Study 30919735 — intervention group
Group type: COMPARATOR
Intervention: Tourniquet only (control group)
Number of subjects: 141
Study 29458902 — intervention group
Group type: EXPERIMENTAL
Intervention: Levonorgestrel-releasing intrauterine system (LNG-IUS)
Number of subjects: 133
Study 29458902 — intervention group
Group type: COMPARATOR
Intervention: Control group (no LNG-IUS)
Number of subjects: 133
Study 26864728 — intervention group
Group type: EXPERIMENTAL
Intervention: Prehabilitation (4-week supervised exercise programme, high-intensity cycle, interval training, 12 sessions)
Number of subjects: 38
Study 26864728 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 38
Study 24866067 — intervention group
Group type: COMPARATOR
Intervention: Conventional scalpel
Number of subjects: 133
Study 24866067 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrocautery
Number of subjects: 133
Study 22116464 — intervention group
Group type: EXPERIMENTAL
Intervention: Trastuzumab plus capecitabine and cisplatin (HXP arm)
Number of subjects: 22
Study 22116464 — intervention group
Group type: COMPARATOR
Intervention: Capecitabine and cisplatin (XP arm)
Number of subjects: 22
Study 19766038 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical abortion at home
Number of subjects: 399
Study 19766038 — intervention group
Group type: COMPARATOR
Intervention: Medical abortion at hospital
Number of subjects: 399
Study 17891666 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing (MI)
Number of subjects: 55
Study 17891666 — intervention group
Group type: COMPARATOR
Intervention: No-treatment control
Number of subjects: 55
Study 16279255 — intervention group
Group type: EXPERIMENTAL
Intervention: Covariate-based constrained randomization procedure
Number of subjects: 0
Study 16279255 — intervention group
Group type: EXPERIMENTAL
Intervention: Blocked and/or stratified designs
Number of subjects: 0
Study 11592727 — intervention group
Group type: EXPERIMENTAL
Intervention: Conjugated linoleic acid (CLA) supplementation (4.2 g/d)
Number of subjects: 53
Study 11592727 — intervention group
Group type: COMPARATOR
Intervention: Olive oil (control)
Number of subjects: 53
Study 9481526 — intervention group
Group type: EXPERIMENTAL
Intervention: Walnut diet (78 g/d walnuts)
Number of subjects: 21
Study 9481526 — intervention group
Group type: COMPARATOR
Intervention: Low fat diet
Number of subjects: 21
Study 7990368 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic irradiation emitted by a copper laser
Number of subjects: 149
Study 7990368 — intervention group
Group type: EXPERIMENTAL
Intervention: Green and yellow light exposure
Number of subjects: 149
Study 7990368 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimodality treatment with laser
Number of subjects: 149
Study 7990368 — intervention group
Group type: COMPARATOR
Intervention: Drug monotherapy (Control)
Number of subjects: 149
Study 2499443 — intervention group
Group type: EXPERIMENTAL
Intervention: Glyburide (15 mg/day)
Number of subjects: 31
Study 2499443 — intervention group
Group type: EXPERIMENTAL
Intervention: Glyburide withdrawal
Number of subjects: 31
Study 31701566 — intervention group
Group type: EXPERIMENTAL
Intervention: Monetary rewards for self‐monitoring of blood glucose and associated behaviours (24-week intervention)
Number of subjects: 60
Study 31068158 — intervention group
Group type: EXPERIMENTAL
Intervention: Attention Bias Modification (ABM) training over fourteen days
Number of subjects: 321